Viread, Genvoya(tenofovir)
Atripla, Biktarvy, Cimduo, Complera, Delstrigo, Descovy, Efavirenz / / Tenofovir Disoproxil, Efavirenz / Emtricitabine / Tenofovir Disoproxil, Emtricitabine / Tenofovir Disoproxil, Genvoya, Odefsey, Stribild, Symfi, Symtuza, Tenofovir Disoproxil, Truvada, Vemlidy, Viread (tenofovir) is a small molecule pharmaceutical. Tenofovir was first approved as Viread on 2001-10-26. It is used to treat acquired immunodeficiency syndrome, chronic hepatitis b, hepatitis b, and HIV infections in the USA. It has been approved in Europe to treat hepatitis b and HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Viread (generic drugs available since 2015-03-18)
CombinationsAtripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Symfi lo, Truvada (generic drugs available since 2015-03-18, discontinued: Temixys)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| STRIBILD | Gilead Sciences | N-203100 RX | 2012-08-27 | 1 products, RLD, RS |
Doravirine
+
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DELSTRIGO | Merck & Co | N-210807 RX | 2018-08-30 | 1 products, RLD, RS |
Efavirenz
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ATRIPLA | Gilead Sciences | N-021937 RX | 2006-07-12 | 1 products, RLD, RS |
Efavirenz
+
Lamivudine
+
Tenofovir disoproxil fumarate
Emtricitabine
+
Rilpivirine hydrochloride
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COMPLERA | Gilead Sciences | N-202123 RX | 2011-08-10 | 1 products, RLD, RS |
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRUVADA | Gilead Sciences | N-021752 RX | 2004-08-02 | 4 products, RLD, RS |
Lamivudine
+
Tenofovir disoproxil fumarate
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIREAD | Gilead Sciences | N-021356 RX | 2001-10-26 | 4 products, RLD, RS |
| VIREAD | Gilead Sciences | N-022577 RX | 2012-01-18 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atripla | New Drug Application | 2020-12-14 |
| atripla access | Export only | 2020-12-14 |
| biktarvy | New Drug Application | 2023-10-31 |
| complera | New Drug Application | 2020-12-09 |
| complera access | Export only | 2020-12-10 |
| delstrigo | New Drug Application | 2023-11-14 |
| descovy | New Drug Application | 2020-12-14 |
| efavirenz, emtricitabine and tenofovir disoproxil fumarate | ANDA | 2023-12-28 |
| efavirenz, lamivudine and tenofovir disoproxil fumarate | ANDA | 2023-11-15 |
| emtricitabine and tenofovir disoproxil fumarate | ANDA | 2024-01-09 |
Show 9 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL FUMARATE, DELSTRIGO, MSD MERCK CO | |||
| 2025-01-27 | NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate, Delstrigo, Msd Merck Co | |||
| 10603282 | 2036-11-29 | DP | |
| 10842751 | 2036-11-29 | DP | |
| 8486975 | 2031-10-07 | DS, DP | U-2395, U-2629, U-3307 |
| Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate, Complera, Gilead Sciences Inc | |||
| 10857102 | 2033-01-14 | DP | |
| 8841310 | 2025-12-09 | DP | U-257 |
| 7125879 | 2025-04-21 | DS, DP | U-257 |
| Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Disoproxil Fumarate, Stribild, Gilead Sciences Inc | |||
| 10039718 | 2032-10-06 | DP | |
| 8633219 | 2030-04-30 | DP | U-257 |
| 8148374 | 2029-09-03 | DS, DP | U-1279 |
| 9891239 | 2029-09-03 | DP | U-257 |
| 7635704 | 2026-10-26 | DS, DP | U-257 |
| 8981103 | 2026-10-26 | DS, DP | |
| 7176220 | 2026-08-27 | DS, DP | U-257 |
| 8592397 | 2024-01-13 | DP | U-248, U-257, U-541, U-750, U-1170 |
| 8716264 | 2024-01-13 | DP | U-257 |
| 9457036 | 2024-01-13 | DP | U-257 |
| 9744181 | 2024-01-13 | DP | U-257 |
| Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate, Atripla, Gilead Sciences | |||
| 8598185 | 2029-04-28 | DP | |
| 9018192 | 2026-06-13 | U-750, U-1170 | |
| 9545414 | 2026-06-13 | DP | U-750, U-1170 |
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF07: Tenofovir disoproxil
— J05AF13: Tenofovir alafenamide
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR03: Tenofovir disoproxil and emtricitabine
— J05AR06: Emtricitabine, tenofovir disoproxil and efavirenz
— J05AR08: Emtricitabine, tenofovir disoproxil and rilpivirine
— J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
— J05AR11: Lamivudine, tenofovir disoproxil and efavirenz
— J05AR12: Lamivudine and tenofovir disoproxil
— J05AR17: Emtricitabine and tenofovir alafenamide
— J05AR18: Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
— J05AR19: Emtricitabine, tenofovir alafenamide and rilpivirine
— J05AR20: Emtricitabine, tenofovir alafenamide and bictegravir
— J05AR22: Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
— J05AR24: Lamivudine, tenofovir disoproxil and doravirine
— J05AR27: Lamivudine, tenofovir disoproxil and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
1320 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 39 | 109 | 151 | 132 | 104 | 510 |
| Hiv | D006678 | — | O98.7 | 28 | 25 | 40 | 74 | 50 | 211 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 19 | 47 | 23 | 50 | 52 | 186 |
| Hepatitis b | D006509 | — | — | 8 | 16 | 11 | 20 | 17 | 70 |
| Healthy volunteers/patients | — | — | — | 25 | — | — | 7 | 2 | 34 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 7 | 14 | 3 | 3 | 26 |
| Hiv-1 | D015497 | — | — | 2 | 7 | 9 | 5 | — | 22 |
| Infections | D007239 | EFO_0000544 | — | — | 6 | 9 | 3 | 3 | 21 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 3 | 3 | 2 | 3 | 4 | 15 |
| Hepatitis c | D006526 | — | B19.2 | 3 | 2 | 1 | 4 | 5 | 14 |
Show 60 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 2 | — | 6 | 8 |
| Covid-19 | D000086382 | — | U07.1 | — | 3 | 5 | — | 2 | 7 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | 1 | — | 1 | 3 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | — | 1 | — | 1 | 2 |
| Breast feeding | D001942 | — | — | — | — | 1 | — | 1 | 2 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | 2 | — | — | 2 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | 1 | — | 1 | 2 |
| B-cell lymphoma | D016393 | — | — | — | — | 1 | — | 1 | 2 |
| Chronic hepatitis d | D019701 | — | — | — | 1 | 1 | — | — | 2 |
| Disease progression | D018450 | — | — | — | — | 1 | — | 1 | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis d | D003699 | EFO_0007304 | — | — | 4 | — | — | 1 | 5 |
| Gender identity | D005783 | — | — | 1 | 1 | — | — | 3 | 4 |
| Behavior and behavior mechanisms | D001520 | — | — | 1 | 1 | — | — | 2 | 3 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 1 | — | — | — | 2 |
| Biliary liver cirrhosis | D008105 | — | K74.3 | — | 1 | — | — | 1 | 2 |
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | — | 2 | — | — | — | 2 |
| Pseudomyxoma peritonei | D011553 | EFO_0007456 | — | — | 2 | — | — | — | 2 |
| Parasitemia | D018512 | — | — | 1 | 1 | — | — | — | 1 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | — | 1 | — | — | — | 1 |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | 1 | — | — | — | 1 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart disease risk factors | D000082742 | — | — | 1 | — | — | — | 1 | 2 |
| Contraception behavior | D003268 | — | — | 1 | — | — | — | 1 | 2 |
| Insulin resistance | D007333 | HP_0000855 | E88.819 | 2 | — | — | — | — | 2 |
| Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | — | 1 |
| Gender dysphoria | D000068116 | — | F64 | 1 | — | — | — | — | 1 |
| Transgenes | D019076 | — | — | 1 | — | — | — | — | 1 |
| Hepacivirus | D016174 | — | — | 1 | — | — | — | — | 1 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Risk reduction behavior | D040242 | — | — | — | — | — | — | 3 | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 3 | 3 |
| Sustained virologic response | D000072230 | — | — | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 2 | 2 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 2 | 2 |
| Self efficacy | D020377 | — | — | — | — | — | — | 2 | 2 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 2 | 2 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 2 | 2 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | — | 1 | 1 |
| Bone density | D015519 | EFO_0003923 | M85 | — | — | — | — | 1 | 1 |
Show 37 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tenofovir |
| INN | tenofovir |
| Description | Tenofovir disoproxil is an organic phosphonate that is the disoproxil ester of tenofovir. A prodrug for tenofovir, an HIV-1 reverse transcriptase inhibitor, tenofovir disoproxil is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. It has a role as a prodrug, a HIV-1 reverse transcriptase inhibitor and an antiviral drug. It is functionally related to a tenofovir (anhydrous). |
| Classification | Small molecule |
| Drug class | antivirals |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 147127-20-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL483 |
| ChEBI ID | 63625 |
| PubChem CID | 5481350 |
| DrugBank | DB00300 |
| UNII ID | W4HFE001U5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Stribild – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Vemlidy – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Viread – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Odefsey – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Atripla – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Truvada – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Descovy – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Complera – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Delstrigo – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Genvoya – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Biktarvy – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Tenofovir
+
Emtricitabine
+
Efavirenz
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tenofovir
+
Emtricitabine
+
Rilpivirine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tenofovir
+
Emtricitabine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tenofovir
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 31,240 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atripla, Atripla access, Biktarvy, Complera, Complera access, Delstrigo, Descovy, Efavirenz, emtricitabine and tenofovir disoproxil fumarate, Efavirenz, lamivudine and tenofovir disoproxil fumarate, Emtricitabine and tenofovir disoproxil fumarate, Genvoya, Odefsey, Stribild, Stribild access, Symfi, Symfi lo, Symtuza, Truvada, Truvada access
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
80,970 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use